002166 Guilin Layn Natural Ingredients Corp.
- 8.36
- -0.91-9.82%
Guilin Layn Natural Ingredients Corp. News
The biotech sector continued to recover, and Rhine Biotech dropped to a standstill
The biotechnology sector continued to recover, with Rhine Biotech falling to a standstill, Zhixiang Jintai-U falling more than 9%, and Nanhua Biotech, Tailin Biotech, and Twining Biotech plummeting.
The concept of synthetic biology was lowered, and the word Rhine Biotech dropped to a standstill
The concept of synthetic biology was lowered. Rhine Biotech dropped to a standstill; Boen Group and Hongbo Pharmaceutical dropped more than 7%, and Azure Biotech and Xinghu Technology all went low.
The synthetic biology concept opened low and went up and down, and Sanyuan Biotech, Fuxiang Pharmaceutical, Meibang Technology, Chengzhi Co., Ltd., and Walter Co., Ltd. followed suit.
The synthetic biology concept opened low and went up and down, and Sanyuan Biotech, Fuxiang Pharmaceutical, Meibang Technology, Chengzhi Co., Ltd., and Walter Co., Ltd. followed suit.
Traditional Chinese medicine stocks fluctuated and rallied, and Rhine Biotech hit a rise or fall
Chinese medicine stocks fluctuated and rallied. Rhine Biotech hit a rise or fall. Tong Ren Tang rose more than 4%, and China Resources 39, Taiji Group, and Yunnan Baiyao rallied.
The synthetic biology concept bottomed out and rebounded. In 7 days and 4, Xintiandi surged more than 10%, while Rundu Co., Ltd., Fujilai, Tuoxin Pharmaceuticals, and Rhine Biotech followed suit.
The synthetic biology concept bottomed out and rebounded. In 7 days and 4, Xintiandi surged more than 10%, while Rundu Co., Ltd., Fujilai, Tuoxin Pharmaceuticals, and Rhine Biotech followed suit.
Express News | Rheinbio: The synthetic biology workshop already has a number of engineers in place, workers are in the recruitment phase, and it is expected that trial production of the workshop will begin in June
Express News | Huafu Securities: There may be more room for alternatives to natural sweeteners in the future
Dragon Tiger List | The concept of synthetic biology is hot, and tourist groups are pouring in! Lukang Pharmaceutical is popular among Fang Xinxia and the Yushin Clan
The top three net purchases on the Dragon Tiger list today are Rhine Biotech, Ruifeng Hi-Tech, and Lukang Pharmaceutical
Synthetic biology concept stocks continued to rise in the afternoon, with Kyodo Pharmaceutical rising and falling 20 cm. Various stocks such as Blue Biotech, Ruifeng Hi-Tech, Lukang Pharmaceutical, Xinghu Technology, Qianjiang Biochemical, and Rhine Biote
Synthetic biology concept stocks continued to rise in the afternoon, with Kyodo Pharmaceutical rising and falling 20 cm. Various stocks such as Blue Biotech, Ruifeng Hi-Tech, Lukang Pharmaceutical, Xinghu Technology, Qianjiang Biochemical, and Rhine Biotech closed. Yiqiao Shenzhou and Tuoxin Pharmaceutical surged more than 14%.
Express News | Rheinbio: Synthetic biotechnology products are expected to be launched and sold one after another in 2024
Express News | Rheinbio: Completed the first phase of research goals for the synthesis of rohan guosin
Rhine Biotech (002166) Company Incident Review Report: The impact of inventory removal has subsided, and the profit side is expected to rise steadily
On April 9, 2024, RHEIN Biotech released its 2023 annual report, and on April 26, 2024, RHEIN Biotech released its report for the first quarter of 2024. Key investment points The impact of inventory removal has subsided, and the profit side continues
Rheinbio (002166): Excellent performance in 24Q1, synthetic biotechnology builds long-term advantages
Key investment points 2023 profit declined slightly. 24Q1 performance surpassed market expectations that the company achieved revenue of 1,494 billion yuan in 2023, an increase of 6.65% over the previous year; realized net profit to mother of 82.51 million yuan, a year-on-year decline
RheinBio (002166.SZ): The overall gross margin for the whole year is expected to remain within a relatively reasonable margin of 25-30%
Gelonghui, April 29丨RheinBio (002166.SZ) held an online exchange on April 26, 2024 to discuss “Based on the first quarter results, does the company have performance guidelines for the full year 2024?” The company replied that in terms of revenue, we will continue to maintain a 15% -20 growth forecast after considering possible quarterly performance fluctuations. In terms of profit, judging by the gross margin level in the first quarter and the price trend of raw materials this year, the overall gross margin for the whole year is expected to remain within a relatively reasonable margin range of 25-30%.
Rheinbio (002166.SZ): Currently, the construction of the synthetic biology plant has entered a relatively advanced stage, and it is expected to be put into use in the third quarter
Gelonghui April 29 丨 Rheinland Biotech (002166.SZ) held an online exchange on April 26, 2024, about “What are the company's latest developments in the synthetic biology business?” The company replied that the construction of the synthetic biology plant has now entered a relatively advanced stage and is expected to be put into use in the third quarter. In terms of research and development, R&D projects for full synthesis and enzymatic transformation technology are progressing normally, and phased results have been achieved. In particular, projects to produce some high-value natural sweetener ingredients through enzymatic conversion technology have passed pilot tests, and can be quickly put into production after the factory is completed.
Rheinbio: Price trends for stevia and Luo Han Guo extract products are expected to increase this year
When surveyed by an agency recently, Rhine Biotech said that it is now the end of April, and the cultivation of raw materials has basically come to an end. Judging from the raw material cultivation situation currently available, it is expected that the prices of stevia extract and Luo Han Guo extract products will be an upward trend this year, especially Luo Han Guo extract. The price of raw materials is expected to gradually recover to an even price this year, which in turn will drive up some of the prices of downstream products.
RheinBio (002166.SZ): Net profit of 267.901 million yuan in the first quarter increased by 34.37% year-on-year
Gelonghui, April 26 | Rhine Biotech (002166.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 341 million yuan, up 35.07% year on year; net profit attributable to shareholders of listed companies was 267.91 million yuan, up 34.37% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 395.709 million yuan, up 372.05% year on year; basic earnings per share were 0.04 yuan.
RheinBio (002166.SZ): The company has not cooperated with cannabis production and processing companies
Gelonghui, April 18 | Rhine Biotech (002166.SZ) said on the investor interactive platform that the company has not yet cooperated with cannabis production and processing companies.
RheinBio (002166.SZ): The company's industrial hemp factory mainly produces CBD and derivatives and other related products
Gelonghui, April 18 | Rhine Biotech (002166.SZ) said on the investor interactive platform that the company's industrial hemp factory mainly produces CBD and related products such as derivatives.
Tianfeng Securities released a research report on April 17 stating that it gave Rhine Biotech (002166.SZ) a purchase rating. The main reasons for the rating include: 1) downstream customers are under pressure to inventory the company's performance; 2) the
Tianfeng Securities released a research report on April 17 stating that it gave Rhine Biotech (002166.SZ) a purchase rating. The main reasons for the rating include: 1) downstream customers are under pressure to inventory the company's performance; 2) the signing of a new 5-year cooperation agreement with the customer, stevia production capacity will be released in 2024, and the natural sweetener business can be expected to continue to grow; 3) the cumulative target revenue amount of this agreement is US$840 million, and the minimum cumulative target revenue amount is US$680 million; 4) the development of the industrial hemp business falls short of expectations, and the market is expected to improve rapidly in the future. (Mainichi Keizai Shimbun)
Analysis
Price Target
No Data
